Accusations Fly as Pharmaceutical Executives Challenge the FDA
The FDA wants more data from drugmakers, who say it’s unfairly moving the goalposts.
This article is for subscribers only.
Welcome to the inaugural edition of Bloomberg’s Health Monitor. Every Thursday we’ll give you a roundup of global developments from boardrooms, labs, politics and public health that are shaping the future of medicine. Sign up now if you’re not already on the list.
Accusations and allegations are roiling the traditionally staid world of pharmaceutical regulation.